FI4027973T3 - Lääkkeensaattoformulaatioita - Google Patents
LääkkeensaattoformulaatioitaInfo
- Publication number
- FI4027973T3 FI4027973T3 FIEP20772437.8T FI20772437T FI4027973T3 FI 4027973 T3 FI4027973 T3 FI 4027973T3 FI 20772437 T FI20772437 T FI 20772437T FI 4027973 T3 FI4027973 T3 FI 4027973T3
- Authority
- FI
- Finland
- Prior art keywords
- formulation
- pharmaceutical formulation
- risperidone
- use according
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900061P | 2019-09-13 | 2019-09-13 | |
| PCT/IB2020/058474 WO2021048817A1 (en) | 2019-09-13 | 2020-09-11 | Drug delivery formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4027973T3 true FI4027973T3 (fi) | 2026-01-14 |
Family
ID=72521677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20772437.8T FI4027973T3 (fi) | 2019-09-13 | 2020-09-11 | Lääkkeensaattoformulaatioita |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US12383493B2 (enExample) |
| EP (2) | EP4027973B8 (enExample) |
| JP (2) | JP7661312B2 (enExample) |
| KR (1) | KR20220062372A (enExample) |
| CN (1) | CN114727946A (enExample) |
| AU (2) | AU2020346455B2 (enExample) |
| BR (1) | BR112022004535A2 (enExample) |
| CA (1) | CA3153793A1 (enExample) |
| DK (1) | DK4027973T3 (enExample) |
| ES (1) | ES3058225T3 (enExample) |
| FI (1) | FI4027973T3 (enExample) |
| HR (1) | HRP20251690T1 (enExample) |
| IL (1) | IL291283A (enExample) |
| LT (1) | LT4027973T (enExample) |
| MX (1) | MX2022003051A (enExample) |
| PL (1) | PL4027973T3 (enExample) |
| PT (1) | PT4027973T (enExample) |
| SI (1) | SI4027973T1 (enExample) |
| WO (1) | WO2021048817A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024511353A (ja) * | 2021-03-17 | 2024-03-13 | メドインセルル エス．エー． | リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤 |
| JP2026501805A (ja) * | 2023-01-10 | 2026-01-16 | メドインセルル エス．エー． | オランザピン組成物及び使用の方法 |
| WO2026013080A1 (en) | 2024-07-08 | 2026-01-15 | InnoCore Technologies Holding B.V. | Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2299393A1 (en) | 1997-08-08 | 1999-02-18 | Sung Wan Kim | Injectable biodegradable block copolymer gels for use in drug delivery |
| CA2474968A1 (en) | 2002-01-31 | 2003-08-07 | Asahi Techno Glass Corporation | Cryopreservation medium for primate embryo stem cells and cryopreservation method |
| ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
| BRPI0919465A2 (pt) | 2008-09-30 | 2015-12-01 | Endo Pharmaceuticals Solutions | dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo |
| CN101584652B (zh) | 2009-06-19 | 2012-06-20 | 上海医药集团股份有限公司 | 利培酮缓释凝胶注射剂及其制备方法 |
| US9023897B2 (en) | 2010-12-29 | 2015-05-05 | Medincell | Biodegradable drug delivery compositions |
| US20130144250A1 (en) * | 2011-10-24 | 2013-06-06 | Endo Pharmaceuticals Solutions Inc. | Implantable drug delivery compositions and methods of treatment thereof |
| EP2866837B1 (en) | 2012-06-27 | 2022-12-14 | Medincell S.A. | Biodegradable drug delivery for hydrophobic compositions |
| EA033537B1 (ru) | 2013-03-11 | 2019-10-31 | Durect Corp | Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью |
| EP3655017B1 (en) | 2017-07-17 | 2025-01-22 | Medincell S.A. | Pharmaceutical composition |
-
2020
- 2020-09-11 MX MX2022003051A patent/MX2022003051A/es unknown
- 2020-09-11 AU AU2020346455A patent/AU2020346455B2/en active Active
- 2020-09-11 JP JP2022516406A patent/JP7661312B2/ja active Active
- 2020-09-11 DK DK20772437.8T patent/DK4027973T3/da active
- 2020-09-11 CA CA3153793A patent/CA3153793A1/en active Pending
- 2020-09-11 EP EP20772437.8A patent/EP4027973B8/en active Active
- 2020-09-11 CN CN202080077874.0A patent/CN114727946A/zh active Pending
- 2020-09-11 FI FIEP20772437.8T patent/FI4027973T3/fi active
- 2020-09-11 EP EP25212808.7A patent/EP4706658A2/en active Pending
- 2020-09-11 ES ES20772437T patent/ES3058225T3/es active Active
- 2020-09-11 PT PT207724378T patent/PT4027973T/pt unknown
- 2020-09-11 US US17/642,410 patent/US12383493B2/en active Active
- 2020-09-11 LT LTEPPCT/IB2020/058474T patent/LT4027973T/lt unknown
- 2020-09-11 SI SI202030708T patent/SI4027973T1/sl unknown
- 2020-09-11 WO PCT/IB2020/058474 patent/WO2021048817A1/en not_active Ceased
- 2020-09-11 HR HRP20251690TT patent/HRP20251690T1/hr unknown
- 2020-09-11 KR KR1020227012200A patent/KR20220062372A/ko active Pending
- 2020-09-11 PL PL20772437.8T patent/PL4027973T3/pl unknown
- 2020-09-11 BR BR112022004535A patent/BR112022004535A2/pt unknown
-
2022
- 2022-03-10 IL IL291283A patent/IL291283A/en unknown
-
2023
- 2023-12-20 US US18/391,243 patent/US12128132B2/en active Active
-
2025
- 2025-04-02 JP JP2025060885A patent/JP2025106353A/ja active Pending
- 2025-05-12 US US19/205,563 patent/US20250268817A1/en active Pending
- 2025-09-30 AU AU2025242078A patent/AU2025242078A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3058225T3 (en) | 2026-03-09 |
| JP2025106353A (ja) | 2025-07-15 |
| US20250268817A1 (en) | 2025-08-28 |
| EP4706658A2 (en) | 2026-03-11 |
| PL4027973T3 (pl) | 2026-03-09 |
| EP4027973B8 (en) | 2025-12-17 |
| CN114727946A (zh) | 2022-07-08 |
| LT4027973T (lt) | 2026-01-26 |
| AU2020346455B2 (en) | 2025-07-03 |
| IL291283A (en) | 2022-05-01 |
| WO2021048817A1 (en) | 2021-03-18 |
| CA3153793A1 (en) | 2021-03-18 |
| US12383493B2 (en) | 2025-08-12 |
| US12128132B2 (en) | 2024-10-29 |
| EP4027973B1 (en) | 2025-11-05 |
| PT4027973T (pt) | 2026-01-05 |
| AU2025242078A1 (en) | 2025-10-23 |
| BR112022004535A2 (pt) | 2022-06-07 |
| SI4027973T1 (sl) | 2026-02-27 |
| HRP20251690T1 (hr) | 2026-02-13 |
| AU2020346455A1 (en) | 2022-03-31 |
| JP2022548616A (ja) | 2022-11-21 |
| DK4027973T3 (da) | 2026-01-12 |
| EP4027973A1 (en) | 2022-07-20 |
| JP7661312B2 (ja) | 2025-04-14 |
| US20240156722A1 (en) | 2024-05-16 |
| MX2022003051A (es) | 2022-06-14 |
| US20220331240A1 (en) | 2022-10-20 |
| KR20220062372A (ko) | 2022-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2582395B1 (en) | Methods for the preparation of injectable depot compositions | |
| CN103491946B (zh) | 可生物降解的药物释放组合物 | |
| US12059397B2 (en) | Calcium lactate compositions and methods of use | |
| KR102189442B1 (ko) | 소수성 조성물용 생분해성 약물 전달 | |
| ES2592527T3 (es) | Composición inyectable antipsicótica de liberación controlada | |
| CY1109425T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων | |
| FI4027973T3 (fi) | Lääkkeensaattoformulaatioita | |
| US12016951B2 (en) | Edaravone pharmaceutical composition | |
| CA2468703A1 (en) | Controlled release polymeric compositions of bone growth promoting compounds | |
| TW200503775A (en) | Pharmaceutical composition and method for treating | |
| KR20160112012A (ko) | 질내 투여용 속용성 정제 조성물 | |
| MX2022000489A (es) | Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla. | |
| US20220071988A1 (en) | Sustained release buprenorphine microspheres (srbm) and methods of use thereof | |
| JP2022548616A5 (enExample) | ||
| KR20210006426A (ko) | 안정한 약제학적 제제 | |
| WO2011112161A1 (en) | Extended release thiocolchicoside tablets | |
| US20240123021A1 (en) | Pharmaceutical compositions | |
| JP7402806B2 (ja) | ４０－ｏ－環状炭化水素エステル及び関連構造のための非経口製剤材料及び方法 | |
| JP2024511353A5 (enExample) | ||
| JPWO2015133580A1 (ja) | 注入可能なポリ乳酸類含有組成物 | |
| JP2003238391A (ja) | 局所投与型徐放性軟膏 | |
| HK1235301A1 (en) | Pharmaceutical compositions comprising lobeglitazone for oral administration |